ضرورت پيشگيري از ترومبوآمبولي وريدي در حاملگي: طراحي يك نرم‌افزار كاربردي

The Necessity of Preventing Venous Thromboembolism in Pregnancy: Designing an Application Software

ترومبوآمبولي وريدي (VTE)شامل: ترومبوز وريدي (DVT) و آمبولي ريه (PE)است و يكي از دلايل مرگ و مير در طي دوره بارداري است. در طي دوران بارداري، تغييرات متعدد در سيستم انعقادي مادر، منجر به انعقادپذيري بالا مي‌شود. نتايج نشان داده است تقريباً يك مورد در هر 200-500 زن در طي بارداري يا پس از بارداري مبتلا به ترومبوآمبولي وريدي و 30 درصد از آنها مبتلا به آمبولي ريه مي‌شوند . در طي سه‌ماهه سوم بارداري و به‌خصوص در دو هفته اول پس از زايمان، خطر VTE در زنان افزايش مي‌يابد. خطر VTE پس از بارداري نيز 5 برابر بيشتر از دوره بارداري است . بارداري به‌تنهايي يكي از عوامل خطر VTE مي‌باشد؛ به‌علاوه برخي از زنان ريسك بالاي پيشرفت VTE را دارند. مهمترين عوامل خطر VTE در طي دوره بارداري شامل: سابقه VTE قبلي، ترومبوفيلي اكتسابي، سابقه VTE قبلي به‌علت جراحي بزرگ، مشكلات طبي (از جمله سرطان، بيماري قلبي و ...)، ترومبوفيلي ارثي پرخطر و .... مي‌باشد.

The Venous thromboembolism (VTE), including venous thrombosis (DVT) and pulmonary embolism(PE) and one of the causes of death during the pregnancy. During the pregnancy, Multiple changes to the mother's coagulation system lead to high coagulation. The results have shown that approximately 1 in every 200-500 women during the pregnancy with venous thromboembolism and 30% in those with pulmonary embolism. During the third trimester of pregnancy, and especially during the first two weeks after childbirth, the risk of (VTE) increases in women. The risk of VTE after pregnancy is 5 times higher than that of the during pregnancy. Also, Pregnancy alone is a risk factor for VTE, And, besides, some women have a high risk of developing the VTE. The most important risk factors for VTE during pregnancy include the previous history of VTE, acquired thrombophilia, history of previous VTE due to major surgery, Medical problems (including cancer, heart disease, etc.), hereditary thrombophilia are high risk (Table 1). Due to numerous clinical conditions and also the risks of an embryo and mother seeking anticoagulant therapy, management during pregnancy should be taken into consideration. Therefore, according to the latest instructions from the Ministry of Health and Medical Education, it was decided to design the software in order to prevent the occurrence of VTE.